Pralatrexate 30 mg/m² IV weekly × 6 of 7-week cycle (PROPEL schedule) — r/r PTCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PRALATREXATE DRUG-LEUCOVORIN |
|---|
| ID | REG-PRALATREXATE-PTCL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
PROPEL trial (O'Connor 2011): r/r PTCL n=111 — ORR 29%, CR 11%, mDOR 10.1 mo, mPFS 3.5 mo. FDA-approved for r/r PTCL after ≥1 prior line. Mucositis is dominant dose-limiting toxicity — MANDATORY folate 1 mg PO daily + B12 1 mg IM q8-10 weeks + oral cryotherapy during infusion to mitigate. Active in PTCL NOS, AITL, ALCL ALK-, transformed MF. Distinct mechanism (selective antifolate) from HDACi / BV / ALK TKI — useful in heavily pretreated.
Used By
Indication
IND-PTCL-2L-PRALATREXATE- IND-PTCL-2L-PRALATREXATE